Echosens shares a mission with the Fatty Liver Foundation to reach into every community in America to ensure asymptomatic individuals receive the screening and care they need.
Read More
Echosens shares a mission with the Fatty Liver Foundation to reach into every community in America to ensure asymptomatic individuals receive the screening and care they need.
NAFLD includes a range of diseases from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Children as young as five are also developing fatty liver disease from too little physical activity and excessive consumption of sugars, sodas, fructose, and corn syrup. Fortunately, NAFLD is reversible if caught early and accompanied by lifestyle changes.
Gastroenterologist and hepatologist, Stephen Harrison, M.D., talks about the alarming growth in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the United States.
Traditionally a disease that primarily attracted the focused attention of hepatologists, nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, has recently raised alarms across a spectrum of health care providers and payers
Traditionally a disease that primarily attracted the focused attention of hepatologists, nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, has recently raised alarms across a spectrum of health care providers and payers
A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).
A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).
After reaching the goal of 100,000 veterans cured of hepatitis C virus (HCV) in as few as two months, the Department of Veterans Affairs (VA) now includes in its contract with Echosens the FibroScan® 430 mini+ portable technology.
Diabetes is one of the leading causes of disability and death in the United States. One in 10 Americans have diabetes — more than 30 million people — and another 84 million adults are at high risk of developing Type 2 diabetes.
